Analytical Data
-
基因名
CSAG1
-
简介
CSAG1 Protein is a potential key player in maintaining centrosome integrity during mitosis, impacting chromosome segregation. The mechanisms underlying its contribution to centrosome stability require elucidation. Its putative involvement highlights significance in mitosis-related cellular events. Further research is essential to unravel precise details of CSAG1's function and its implications for centrosome integrity during mitosis. CSAG1 Protein, Human (HEK293, Fc) is the recombinant human-derived CSAG1 protein, expressed by HEK293 , with N-hFc labeled tag.
- Application
-
别名
Putative chondrosarcoma-associated gene 1 protein; CT24.1; Cancer/testis antigen CSAGE; CSAGE
-
种属
Human
-
表达系统
HEK293
-
标签
N-hFc
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q6PB30-1
-
表达区间
D20-P78
-
蛋白长度
Full Length of Isoform-1 Mature Protein
-
分子量
34 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CSAG1, or cancer/testis antigen 1, is a protein that has garnered significant attention in cancer research due to its unique expression profile. It is predominantly expressed in testicular germ cells and various cancer types, particularly melanoma and other solid tumors, while being largely absent in normal somatic tissues. This restricted expression makes CSAG1 an attractive target for immunotherapy, as it can potentially elicit a robust immune response with minimal off-target effects. Previous studies have indicated that CSAG1 can induce humoral and cellular immune responses in cancer patients, suggesting its potential as a therapeutic vaccine or as part of a tumor antigen-targeted therapy. Furthermore, the characterization of CSAG1 at the molecular level has provided insights into its role in tumorigenesis and potential mechanisms of immune evasion. Ongoing research focuses on the recombinant production of CSAG1 to facilitate the development of diagnostic and therapeutic applications, exploring its potential as a biomarker for cancer diagnosis and prognosis. As the landscape of cancer treatments evolves, CSAG1 continues to represent a promising avenue for the development of novel immunotherapeutic strategies aimed at harnessing the body’s immune system to combat malignancies.
